BidaskClub upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a hold rating to a buy rating in a research report released on Tuesday morning.

Other equities analysts have also issued reports about the stock. ValuEngine lowered shares of Assembly Biosciences from a hold rating to a sell rating in a report on Thursday, December 7th. Zacks Investment Research upgraded shares of Assembly Biosciences from a sell rating to a hold rating in a report on Tuesday, October 10th. B. Riley assumed coverage on shares of Assembly Biosciences in a report on Friday, January 5th. They issued a neutral rating and a $35.00 price objective on the stock. Finally, Jefferies Group assumed coverage on shares of Assembly Biosciences in a report on Wednesday, November 8th. They issued a buy rating and a $50.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. Assembly Biosciences currently has an average rating of Hold and an average price target of $39.25.

Assembly Biosciences (ASMB) opened at $46.25 on Tuesday. Assembly Biosciences has a fifty-two week low of $18.60 and a fifty-two week high of $52.37.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.17. The company had revenue of $2.66 million during the quarter, compared to analyst estimates of $1.25 million. equities research analysts anticipate that Assembly Biosciences will post -3.22 earnings per share for the current fiscal year.

In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $45.04, for a total transaction of $45,040.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 19.60% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the business. Nationwide Fund Advisors acquired a new stake in Assembly Biosciences during the 2nd quarter worth approximately $161,000. Parametric Portfolio Associates LLC lifted its holdings in Assembly Biosciences by 13.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 1,203 shares in the last quarter. Legal & General Group Plc acquired a new stake in Assembly Biosciences during the 2nd quarter worth approximately $212,000. Wells Fargo & Company MN acquired a new stake in Assembly Biosciences during the 2nd quarter worth approximately $213,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in Assembly Biosciences by 15,448.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,195 shares of the biopharmaceutical company’s stock worth $232,000 after buying an additional 11,123 shares in the last quarter. Institutional investors own 61.31% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Assembly Biosciences (ASMB) Raised to “Buy” at BidaskClub” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2018/02/02/assembly-biosciences-asmb-raised-to-buy-at-bidaskclub.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.